phase 1_initiation
saveShenzhen MagicRNA Biotech Co Ltd — HN-2302 (Phase I Trial Initiation)
community read0 votes
Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)
Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)